מסביב לעולם, יותר ממיליון אנשים מטופלים עם Cosentyx. עבורנו, זו עדות לרמה עמוקה של אמון, ביטחון ושביעות רצון, שחשים מטופלים ואנשי מקצוע כאחד.
רצינו להגיד לך תודה על תפקידך החשוב במסע לשיפור חיי המטופלים ולשתף אותך בסרטון מיוחד שהכנו:
Therapeutic indications
Adult Plaque psoriasis - Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Paediatric plaque psoriasis - Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
Hidradenitis suppurativa (HS) - Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.
Psoriatic arthritis - Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Axial spondyloarthritis (axSpA)
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis) - Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis (nr-axSpA) - Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and / or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs).
Juvenile idiopathic arthritis (JIA)
Enthesitis-related arthritis (ERA) - Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
Juvenile psoriatic arthritis (JPsA) - Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
Dear physician, for more information and PI as approved
by the Israeli Ministry of Health please click:
Cosentyx PI
1 Novartis data on file. Cosentyx cumulative patients served. January 2023
COS-PSO-RTE-19.24 Apr-2024
הירשמו לקבלת עדכונים בנושאים שעלו בכתבה
נושאים קשורים: וידאו
